Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146

摘要: Most assays to detect circulating tumor cells (CTCs) rely on EpCAM expression cells. Recently, our group reported that in contrast other molecular breast cancer subtypes, “normal-like” cell lines lack and are thus missed when CTCs captured with EpCAM-based technology [J Natl Cancer Inst 101(1):61–66, 2009]. Here, the use of CD146 is introduced EpCAM-negative CTCs, thereby improving CTC detection. were assessed panel 41 lines. Cells from 14 lines, 9 which normal-like, spiked into healthy donor blood. Using CellSearch™ technology, 7.5 ml whole blood was enriched for by adding ferrofluids loaded antibodies against and/or followed staining Cytokeratin DAPI. Hematopoietic endothelial (CECs) counterstained CD45 CD34, respectively. A similar approach applied samples 20 advanced patients. Eight normal-like lacked but did express CD146. Five these 8 could be adequately recovered anti-CD146 ferrofluids. Of patients whose enumerated anti-EpCAM ferrofluids, had CD146+ CTCs. frequently can present peripheral disease. Combined likely improve detection